Introduction: Cisplatin (Cis), a key cancer chemotherapy drug, faces limitations such as dose-dependent side effects and resistance. Photobiomodulation therapy (PBMT) shows promise as an adjuvant therapy to enhance Cis efficacy and reduce side effects. Methods: A systematic review was conducted to evaluate the combined effects of PBMT and Cis on various cancers. After searching five databases using relevant keywords, nine studies were included, encompassing both in vitro and in vivo models. Results: Most in vitro studies showed a synergistic effect, with enhanced cancer cell inhibition, apoptosis induction, and reduced cell viability compared with Cis alone. The animal model confirmed these findings, showing PBMT mitigated Cis-induced acute renal failure. Conclusion: Mechanistically, PBMT may increase reactive oxygen species generation, cytochrome c release, modulate cellular metabolism, and involve the miR-124/STAT3 signaling pathway. Combining PBMT with Cis appears to be a safe and effective cancer treatment strategy, synergistically inhibiting cancer cell growth and reducing side effects. Further clinical trials are needed to validate these findings.
Jafarzadeh et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: